PYXIS ONCOLOGY INC
PYXSNASDAQTrading Snapshot
- Day Range
- $2.88 – $2.92
- 52-Week Range
- $1.03 – $5.55
- Volume
- $2.54B
- Avg Volume
- $2.02B
- Shares Outstanding
- 63.4M
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $4M
- P/E Ratio
- -2.1
- P/S Ratio
- 16.6x
- EPS (TTM)
- $-1.39
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.4%
Why Investors Own PYXS
- ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PYXIS ONCOLOGY INC
PYXS
StockOtter · stockotter.spaceAbout PYXIS ONCOLOGY INC
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previous
Pyxis Oncology Announces Proposed Public Offering
BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a reg
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) vs. ProKidney (NASDAQ:PROK)
ProKidney (NASDAQ: PROK - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the stren
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the s
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology Inc. (NASDAQ:PYXS) on Wednesday shared updated data from its Phase 1 trial evaluating micvotabart pelidotin (MICVO).